Otium Capital

Otium Capital is a Paris-based multi-strategy family office and active investor founded by entrepreneur Pierre-Edouard Sterin. The firm operates across direct venture investments, incubations, consolidation platforms, and sector-specific holdings, with a notably long-term horizon. For physician AI and digital health founders, Otium is a less conventional but genuinely useful name when you want patient capital and a partner willing to act outside standard VC timelines.

The thesis is broad and deliberately flexible, covering technology, services, consumer, healthcare, and life sciences, with active interest in digital health, care delivery, tech-enabled services, and life sciences platforms. The firm has built consolidation vehicles such as Enosium Life Science to roll up assets in specific niches and is comfortable backing both pure software and services-heavy models. AI applications fit the lens when they are commercially defensible rather than research-stage.

Check sizes typically range from two hundred and fifty thousand to one million dollars at the early end, with capacity to do much larger transactions through the firm’s broader platform when the opportunity warrants. Stage is broad, from pre-seed through growth, depending on the strategy. Geography is European with a strong French focus, plus selective activity beyond Europe.

The team mixes investing, operating, and incubation backgrounds, with a structure that allows the firm to act as venture investor, builder, or strategic acquirer depending on the situation. Diligence varies by strategy; expect a different process for a venture cheque than for an incubation or platform investment. Decisions tend to be principal-driven, which means timelines can be fast when conviction is high.

The right way to approach is through a portfolio CEO, a French operator-investor, or a corporate finance contact familiar with Otium’s various strategies. Cold inbound through the website is read but works less well than warm routes given the breadth of the firm’s activities. When you reach out, identify which strategy fits your situation: a direct venture cheque, an incubation, or a platform play. Lead with the founder story, the commercial wedge, and a clear thesis on why patient capital and operational support unlock value. The right time to engage is when you have a defined commercial story and a clear sense of which Otium strategy is the right entry point. Founders looking for a standard VC process, fixed timelines, and committee-driven decisions may find Otium’s flexibility confusing rather than helpful; founders open to a less conventional, principal-led partner will find a serious option in Paris.